↓ Skip to main content

Dove Medical Press

Article Metrics

Efficacy and safety of olopatadine hydrochloride 0.77% in patients with allergic conjunctivitis using a conjunctival allergen-challenge model

Overview of attention for article published in Clinical Ophthalmology, September 2015
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (73rd percentile)
  • High Attention Score compared to outputs of the same age and source (94th percentile)

Mentioned by

twitter
3 tweeters
patent
10 patents

Citations

dimensions_citation
15 Dimensions

Readers on

mendeley
16 Mendeley
Title
Efficacy and safety of olopatadine hydrochloride 0.77% in patients with allergic conjunctivitis using a conjunctival allergen-challenge model
Published in
Clinical Ophthalmology, September 2015
DOI 10.2147/opth.s83263
Pubmed ID
Authors

Gail Torkildsen, Abhijit Narvekar, Mark Bergmann

Abstract

Symptom relief for the duration of 24 hours after treatment would benefit patients with allergic conjunctivitis. To compare the safety and efficacy of olopatadine 0.77% with vehicle or olopatadine 0.2% in patients with allergic conjunctivitis in a conjunctival allergen-challenge clinical study. In this Phase III, multicenter, double-masked, parallel-group, randomized trial, patients with allergic conjunctivitis received olopatadine 0.77%, its vehicle, or olopatadine 0.2%, administered once at visits 3A (day 0), 4A (day 14 ±2), and 5 (day 21 +3). Allergic conjunctivitis-associated sign and symptom assessments included ocular itching, conjunctival redness, total redness, chemosis, and tearing scores. Adverse events and ocular safety parameters were also assessed. A total of 202 qualifying patients were randomized. Olopatadine 0.77% was superior (P<0.001) to vehicle for treatment of ocular itching at 3, 5, and 7 minutes postchallenge at onset of action and 16- and 24-hour duration of action. Conjunctival redness mean scores were significantly lower for olopatadine 0.77% versus vehicle at all three post-conjunctival allergen-challenge time points: onset (-1.52 to -1.48; P<0.001), 16 hours (-1.50 to -1.38; P<0.01), and 24 hours (-1.58 to -1.38; P<0.05). At 24 hours, olopatadine 0.77% was superior to olopatadine 0.2% at all three postchallenge time points for ocular itching (P<0.05), conjunctival redness (P<0.05), and total redness (P<0.05). No clinically relevant differences in safety parameters or adverse events were observed between the treatment groups. Olopatadine 0.77% is superior to both its vehicle and olopatadine 0.2% for the treatment of allergen-mediated ocular itching and conjunctival redness. Ocular itching symptom relief is maintained over 24 hours, supporting once-daily dosing and demonstrating a comparable safety profile to olopatadine 0.2%.

Twitter Demographics

The data shown below were collected from the profiles of 3 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 16 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 16 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 5 31%
Other 3 19%
Professor 1 6%
Student > Doctoral Student 1 6%
Student > Master 1 6%
Other 2 13%
Unknown 3 19%
Readers by discipline Count As %
Medicine and Dentistry 7 44%
Agricultural and Biological Sciences 1 6%
Nursing and Health Professions 1 6%
Biochemistry, Genetics and Molecular Biology 1 6%
Computer Science 1 6%
Other 2 13%
Unknown 3 19%

Attention Score in Context

This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 September 2021.
All research outputs
#5,169,844
of 19,225,771 outputs
Outputs from Clinical Ophthalmology
#360
of 2,781 outputs
Outputs of similar age
#66,198
of 251,521 outputs
Outputs of similar age from Clinical Ophthalmology
#4
of 85 outputs
Altmetric has tracked 19,225,771 research outputs across all sources so far. This one has received more attention than most of these and is in the 72nd percentile.
So far Altmetric has tracked 2,781 research outputs from this source. They receive a mean Attention Score of 3.5. This one has done well, scoring higher than 86% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 251,521 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 73% of its contemporaries.
We're also able to compare this research output to 85 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 94% of its contemporaries.